Objective: We described the magnitude, type, and factors associated with first-line antiretroviral therapy (ART) modification in HIV-1-infected adults on ART in Jos, Nigeria. Method: Data on 6309 patients initiated on first-line ART between January 2004 and December 2006 were analyzed retrospectively. Factors predictive of modification to initial ART were assessed by chi-square and multivariable logistic regression analysis. Results: Overall, 5212 (83%) included patients incurred a modification (73.3% drug substitution and 9.7% drug switch) to their initial first-line ARV regimen during a median (interquartile range) follow-up period of 7 (3-8) years. Drug substitutions of zidovudine (ZDV) were less likely than of tenofovir (TDF; adjusted odd ratio [AOR] 0.6; 95% confidence interval [CI]: 0.51-0.71), and Drug substitutions of efavirenz (EFV) were more likely than of nevirapine (NVP)containing (AOR 1.82; 95% CI: 1.42-2.33) regimens. Predictors of switch to second-line regimen include older age (AOR 2.05; 95% CI: 1.68-2.51), CD4 count 100 cells/mm 3 (AOR 1.89; 95% CI: 1.49-2.37), EFV compared to NVP (AOR 1.38; 95% CI: 1.02-1.88), and drug toxicity (AOR 1.90; 95% CI: 1.48-2.43). Conclusion: Modification to initial ART was common in this study. Further evaluation of the contribution of guideline changes on regimen modification and treatment outcomes is recommended.
Introduction
The benefits of treating HIV infection with combination antiretroviral therapy (cART) have been well described, including durable viral suppression, quantitative and qualitative immune recovery, reductions in morbidity and mortality, and prevention of HIV transmission. [1] [2] [3] [4] [5] [6] As survival of HIV-infected patients continues to improve, more attention is being focused on factors that ensure long-term success of ART and ART programs.
Maximal regimen durability with regard to safety and efficacy is a critical factor for long-term success of ART. 7 Modification to ART presents a number of challenges such as limited therapeutic alternatives, viral cross-resistance between possible alternatives, and overlapping of toxicity between potential alternatives, in addition to adherence and quality-of-life challenges. [8] [9] [10] [11] In sub-Saharan Africa (SSA), where limited drug options are common due to limited resources, regimen durability takes on an even more important role than in industrialized countries. Most public sector ART programs, which are donor driven, often adopt treatment guidelines that promote a public health approach to the management of HIV, and providers are constrained to operate with a limited formulary. 12 It becomes imperative to carefully select ARV regimen at initiation and understand the determinants of regimen change in order to ensure treatment success.
There are limited data on the magnitude and predictors of regimen durability in ART programs in Nigeria, where there has been rapid scaling up of ART services over the past decade. 13 In this study, which spans 8 years, we aimed to determine the magnitude and type of modification of first-line ART among a large cohort of HIV-1-infected patients who initiated ART at the Jos University Teaching Hospital (JUTH) as well as to identify baseline demographic and clinical characteristics that predict first-line regimen modification.
Methods

Setting
The comprehensive HIV care and treatment program at JUTH located in North Central Nigeria, started in 2002 with support from the Federal Government of Nigeria. In 2004, there was a rapid scaling up of ART services with further support from the Harvard School of Public Health (HSPH) and AIDS Prevention Initiative in Nigeria (APIN), with funding from the US President's Emergency Plan for AIDS Relief (PEPFAR). The JUTH HIV clinic provides comprehensive HIV care and treatment services for the city of Jos and serves as a referral center for health facilities in Plateau State and other states in the region. Currently, the JUTH HIV clinic provides HIV care and treatment services to over 14 000 HIV-infected adults and children.
Study Population
The study population included HIV-1-infected, treatmentnaive adults (aged 15 years and older) who initiated their first ART between January 2004 and December 2006. All patients included in the analysis initiated nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART, which included an NNRTI (nevirapine [NVP] or efavirenz [EFV]) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs), often stavudine (d4T), didanosine (DDI), zidovudine (ZDV), tenofovir (TDF), or abacavir (ABC) plus lamivudine (3TC). Patients were excluded from the analysis if they made only 1 pharmacy pickup for their antiretroviral (ARV) medications, if they initiated first-line ART with a triple NRTI regimen or a protease inhibitor (PI)-based regimen, or if they were ART experienced.
Standard of Care
Per the standard care at the JUTH HIV clinic, all patients had their HIV-1 infection status confirmed positive by Western blot. The decision to initiate ART was based on the Nigerian National Adult ART guidelines. 14 At the time of the study, ART was initiated based on a CD4 count of 350 cells/mm 3 with HIV-related symptoms or a CD4 count <200 cells/mm 3 regardless of the symptoms. 14 Selection of the initial first-line ARV regimen was also based on the national ART guidelines. An electronic database (FileMaker Pro, v10; FileMaker, Inc, Santa Clara, California, USA) of patients' demographic, clinical, pharmacy, and laboratory data designed by the Harvard PEPFAR/APIN program was utilized in the clinic. Dispensing of ART occurred monthly and at scheduled clinical visits, and each time a medication was dispensed at the clinic (pharmacy pickup), data were documented in the electronic pharmacy database. The ART efficacy and toxicity was monitored regularly based on the standard clinical procedures. Free-of-charge ARV drugs and laboratory monitoring were provided to the patients.
Definition of Terms and Outcome Variable
The outcome variable included the modification of a first-line ARV regimen, which is described as drug substitution or drug switch. This was evaluated between the first documented pharmacy pickup at the time of ART initiation (baseline) and the last pharmacy pickup occurring within the end of the study period (December 31, 2011). Drug substitution was defined as the replacement of one or more drugs in the first-line ARV regimen (NRTI or NNRTI) with another drug from the same ARV class (NRTI or NNRTI), for example, an NNRTI substitution from NVP to EFV or an NRTI substitution from d4T to ZDV. However, a change between 3TC and emtricitabine (or vice versa) was not classified as a drug substitution because these 2 NRTIs are considered therapeutically interchangeable. 15 Drug switch was defined as a change from the first-line NNRTI-based ART to the second-line PI-based ARV regimen. Per treatment guidelines, 14 drug switches are usually done after confirmation of virologic failure. Virologic failure was defined as plasma viral load (VL) of above 1000 copies/ mL on 2 consecutive VL measurements after 6 to 12 months of cART initiation, with documented optimal ART adherence.
Variables Collected
All data were extracted from the Harvard PEPFAR/APIN Plus program database. The patient data assessed pre-ART (baseline) included demographics (sex and age), World Health Organization (WHO) clinical stage of HIV, coinfection with hepatitis B virus (HBV), coinfection with active tuberculosis (TB) at baseline, and CD4 count. Regimen data assessed included initial first-line ARV regimen (by NNRTI and NRTI backbone) and last ART regimen dispensed during the study period (by NNRTI or PI and NRTI backbone). Data on reported drug toxicity and the date of documentation were also collected. The HIV-1 VL assay was performed using Roche COBAS Ampiclor HIV-1 Monitor, version 1.5 (Roche Diagnostics GmbH, Mannheim, Germany), while the CD4 count was determined using CyFlow (Partec, Munster, Germany). Hepatitis B surface antigen (HBsAg) was determined using enzyme immunoassay (Monolisa HBsAg Ultra3; Bio-Rad, Hercules, USA).
Ethical Considerations
All patients enrolled in the clinic provided written informed consent for the use of their data for research. The ethical committee of JUTH approved retrospective analysis of existing data as part of the program treatment and study protocol, and the use of secondary data was approved by HSPH.
Statistical Analysis
Continuous variables were described by means and standard deviation or median and interquartile range (IQR, presented as the upper value of the 25% and 75% quartiles), as appropriate based on data distribution, and categorical variables were described using frequencies and proportions. Univariate analysis to evaluate the baseline patient or regimen factors associated with the outcome variable (drug substitution or drug switch) was performed using chi-square. For the multivariate analysis, the following predictor variables were stratified: age (<35 years versus 35 years, which was the median age for the population), WHO clinical stage (stage 3 or 4 versus stage 1 or 2), and CD4 count (100 cells/mm 3 versus >100 cells/mm 3 ). World Health Organization clinical stages 3 and 4 and CD4 count 100 cell/mm 3 were representative of severely immunocompromised patients. Multivariate logistic regression analysis was performed to evaluate independent predictors of drug substitution or drug switch (dependent variables); results are presented using an adjusted odds ratio (AOR) with 95% confidence intervals (CIs). All variables that were significant in the univariate analysis to a P value <.25 were included in a multivariate model as well as age and sex to account for any residual confounders. All analyses were performed using IBM SPSS Statistics for Windows, Version 20 (IBM Corp, Armonk, New York, USA).
Results
Baseline Patient Characteristics
A total of 6309 patients were eligible for inclusion in the study and were followed for a median (IQR) of 7 (3) (4) (5) (6) (7) (8) years. Fortyone patients initiated ART during the specified period but were excluded from the analysis, that is, 2 were ART experienced and 39 initiated a triple NRTI regimen. Table 1 summarizes patient demographics and baseline clinical and regimen characteristics overall and for those with drug substitution or drug switch. In all, the study population was largely female (66%) with a median 
Initial First-Line ART Modification
Overall, 5212 (83%) included patients incurred a modification to their initial first-line ARV regimen, that is, 4623 (73.3%) experienced an NRTI and/or NNRTI drug substitution and 589 (9.3%) experienced a drug switch from NNRTI-based to PI-based ART.
Drug substitution. Of the 4623 patients who incurred a drug substitution, 2789 (44%) involved a single NRTI substitution, 484 (8%) involved a single NNRTI substitution, and 1350 (22%) involved both an NRTI and an NNRTI substitution. Tables 1 and  2 summarize factors associated with NRTI and/or NNRTI drug substitutions on bivariate and multivariate analyses, respectively. In bivariate analysis (Table 1) , drug substitution rates were significantly higher among patients who initiated EFVbased ART (79% versus 73% for NVP-based ART, P < .001) and were lowest among those who initiated ZDV/3TC (57%, P < .001) across NRTI backbones. Differences were also noted by HBV and across WHO clinical stage groups. After adjustment for confounding factors (Table 2) , several regimen and patient baseline factors were identified as predictors of drug substitution. Patients who initiated EFV-based ART were at an 82% greater odds of experiencing a drug substitution than those who initiated NVP-based ART (AOR 1.82; 95% CI: 1.42-2.33). Across NRTIs, patients who received ABC, d4T, or DDI were at 4.4-, 3.5-, and 3.8-fold, respectively, greater odds to experience a drug substitution than those who received TDF, whereas those who received ZDV were 40% less likely to have a drug substitution (AOR 0.6; 95% CI: 0.51-0.71). Baseline patient characteristics identified as independent predictors of drug substitution included HBV coinfection, and more advanced HIV disease, evidenced by CD4 count 100 cells/mm 3 or WHO clinical stage 3 or 4. Documentation of drug toxicity throughout the study period was not associated with drug substitution.
Drug switch. Tables 1 and 2 summarize factors associated with drug switch for the 589 (9.4%) patients who switched from NNRTI-based to PI-based ART. In the univariate analysis (Table 1) , drug switch was significantly higher in male than in female patients (11% versus 9%; P ¼ .03) and more common in patients >45 years (13%; P < .001) than across the different age-groups. Although there was no significant difference in the occurrence of drug switch across the NRTI groups, it was significantly higher in those on EFV than those on NVP-based ART (14% versus 9%; P < .001). There were more drug switches in patients who had documentation of drug toxicity than those with no documented drug toxicity (17% versus 9%; P < .001). After adjustment for confounders (Table 2) , the odds of drug switch were doubled in patients aged >35 compared to those 35 years (AOR 2.05; 95% CI: 1.68-2.51).
Other independent predictors of drug switch were advanced 
Discussion
This study evaluated a large clinical cohort of patients initiating ART, who were followed for an 8-year time period. A high incidence of ART modification was observed among patients included in our analysis, wherein the within-class drug substitutions of the NRTI and/or NNTRI accounted for the majority, while drug switch from NNRTI-based to PI-based second-line ART was low. This study, to the best of our knowledge, is the first report of ARV regimen durability in Nigeria.
In terms of frequency, the high rates of first-line ART modification observed in this study are similar to that reported in other cohort studies in industrialized countries 16, 17 but lower than a recent study in Kenya. 18 Although we did not quantify the impact of treatment guideline changes on the magnitude of first-line ART modification in our study, the contribution of changes in policy was likely a significant contributor to the high rates of drug substitution observed in our study. Between 2004 and 2006, a wide variety of ARV regimens were available for use within the Harvard PEPFAR/APIN Plus program. However, with time, regimen options were streamlined based on the changing programmatic ART guidelines, which were largely based on WHO and national treatment guidelines, program experience, and new scientific evidence. According to the WHO 2003 treatment guideline, d4T/3TC or AZT/3TC in combination with NVP or EFV was the preferred first-line regimen, although EFV was largely avoided in women of childbearing potential or in pregnant women. 19 In 2006, however, AZT/ 3TC or TDF/3TC in combination with NVP or EFV became the preferred first-line regimen. 20 In the 2010 guideline, the use of d4T was discouraged, given the high rates of lactic acidosis, lipodystrophy, peripheral neuropathy, and other mitochondrial toxicity-related adverse effects observed with its use. 21 As a result, about 88% of patients in our cohort who initiated a d4T-containing regimen during the study period experienced a drug substitution as their regimen was modified to a less toxic NRTI backbone. Similarly, the use of DDI, that has a similar toxicity profile as d4T, was discontinued in 91% of all patients initiated on DDI. Additionally, programmatic ARV quantification assumptions gave priority to extant treatment guidelines and limited the choice of regimens available for treatment. Hence the ARV regimens of stable patients were modified in some cases based on product availability, moving toward regimens with more favorable toxicity profiles or more convenient dosage formulations. The adherence, quality of life, and virologic implication of regimen modification in a stable patient in this setting are unknown and needs to be further investigated.
Interestingly, in our study, we observed that patients who initiated EFV-based ART were at significantly greater odds of experiencing a drug substitution and drug switch as compared to those who initiated NVP-based ART. Prior studies have reported conflicting findings to this point, either in agreement 22 or in disagreement with ours. 23, 24 Our finding is important, considering that the fixed-dose combination consisting of EFV, 3TC þ emtricitabine, and TDF is now the preferred firstline ART regimen. 25 However, given the limitations of our study, we are unable to characterize the reason for drug substitution, which is important in evaluating whether the higher rate of modification noted with EFV is a result of efficacy or toxicity. Further investigation without our cohort is required.
Considering the NRTI background, the higher rates of drug substitution noted among patients who initiated d4T-, DDI-, or ABC-containing therapy are well supported by changes to ART guidelines in favor of safer and now more affordable options, 25 such as TDF. However, we also observed a lower risk of drug substitution among patients who initiated first-line ART with an AZT-containing regimen compared to TDF, which differs from prior studies, [26] [27] [28] [29] and is contrary to the most recent ART guidelines that recommend TDF as the preferred NRTI. 25 From our study, we are unable to discern the rationale for drug substitution and, therefore, unable to evaluate whether differences in toxicity, programmatic recommendations, ARV drug availability, or other factors impacted this finding. However, given the shift toward TDF-containing regimen as the preferred firstline ART in SSA, 25 it remains important to further evaluate these patterns of drug usage.
Furthermore, we observed that patients with severe immunodeficiency at the start of ART (CD4 count 100 cells/ mm 3 ) and advanced HIV disease (WHO clinical stages 3 and 4) had a higher likelihood of drug substitution and drug switch. This association has been reported in a recent study in industrialized countries. 26 It lends credence to the findings which suggest that treatment initiation at higher CD4 count thresholds is advantageous in achieving better treatment outcomes, which is also favored by current treatment guidelines. 25 We also identified HBV coinfection as an important factor for drug substitution. This evolved over the course of the study, in that clinician became more aware of preferred treatment practices for HBV and simultaneously, TDF availability became more widespread. [27] [28] [29] Both tending toward the expected shift in NRTI backbone for many of these patients who were (hopefully) moved to more optimal regimens.
Unlike the Kenya study, we found a lower likelihood of drug substitution in older patients (>35 years), 18 whereas the odds of drug switch almost doubled in older patients in our study, suggesting increased risk of virologic failure in older patients at ART initiation, synonymous with the finding of Fong et al. 30 Unlike a previous study, 31 surprisingly we did not find a significant association between drug substitution and drug toxicity; however, drug toxicity was predictive of drug switch. Drug side effects are associated with poor adherence to therapy, 32 virologic failures, and higher drug switch rates, 33, 34 as observed in this study.
Most patients in our study cohort were retained on NNRTIbased first-line ART during the study period, suggestive of high NNRTI-based regimen durability in our patient cohort. This pattern has been reported in other African settings. 35 Based on the treatment guidelines, PI-based ART is reserved for patients who failed the first-line, NNRTI-based regimen and who, therefore, require second-line ART. Although the observed drug switch rates of less than 10% in our cohort is suggestive of highly effective and durable NNRTI-based ART, it is worth noting that the requirement for documented adherence and a repeat VL >1000 copies/mL may have resulted in a lag of drug switching relative to virologic failure. To the latter point, maintaining patients on a failing regimen has implications for the accumulation of more resistant mutant strains. [36] [37] [38] Promptly identifying patients with virological failure who are in need of a drug switch is important to the preservation of treatment options and the achievement of optimal treatment outcomes.
Our study had some limitations that must be carefully considered when interpreting our findings. First, while the criteria for drug switch were established in the clinic, the reasons for drug substitutions were poorly documented. Thus, it remains unclear whether there were additional clinical (eg, drug interactions or opportunistic coinfections), laboratory (eg, laboratory values associated with drug toxicities), or programmatic factors (eg, treatment guideline changes or ARV supply chain considerations) that were independent predictors of drug substitution. Second, the impact of TB coinfection on drug-substitution or drug-switch rates was not evaluated as data were only available for 18% of our cohort, which is not a representative sample.
Conclusion
Among patients initiating first-line ART between 2004 and 2006 in Nigeria, over 80% experienced a regimen modification within a period of 8 years, commonly an NRTI and/or NNRTI drug substitution. Drug-switch rates from NNRTI-to secondline PI-based regimens were low (<10%), suggesting high durability of NNRTI-based regimen in our setting. Significant predictors of switch to second-line regimen were older age, greater immunosuppression, EFV compared to NVP, and drug toxicity. Our study highlights the dynamic nature of first-line ARV regimens used in our setting over time, which were likely driven by the dynamic nature of ART guidelines over this period. The need to evaluate the contribution of guideline changes on regimen modification and treatment outcomes is desirable in this setting.
